Gertrude B. Elion (1918-2019) was an American biochemist and pharmacologist whose pioneering work in drug development significantly advanced pharmaceutical chemistry. She co-developed several important drugs, including the first effective treatment for leukemia, 6-mercaptopurine, in the 1950s, which became a cornerstone in cancer therapy. Elion's innovative approach involved using knowledge of biochemistry and molecular biology to design drugs that targeted specific biochemical pathways, a method that laid the groundwork for modern drug design. Alongside her colleague George H. Hitchings, she received the Nobel Prize in Physiology or Medicine in 1988 for their contributions to the development of drugs that treat various diseases, including autoimmune disorders and viral infections. 

Elion's work led to the creation of the antiviral drug acyclovir in 1977, which became a critical treatment for herpes simplex virus infections. She was also instrumental in developing azathioprine, an immunosuppressant used in organ transplantation. Throughout her career, Elion worked at Burroughs Wellcome Co. in North Carolina, where she spent over 40 years conducting research. Her legacy continues to influence pharmaceutical chemistry, as her methods of rational drug design are now standard practice in the industry, paving the way for the development of targeted therapies in modern medicine.